Why the study?
An updated, evidence-based framework specifically designed for the Saudi population was needed to address the rising burden of CVDs through prevention, lifestyle modification, and optimized pharmacologic management.
Cross-Sectional (n=11,381)
Yes
The 2025 Saudi Heart Association guidelines provide an updated, evidence-based framework for cardiovascular disease prevention tailored to the Saudi population, addressing significant local risk factors such as a 19.8% tobacco use prevalence.
Tobacco control should be prioritized in Saudi CVD prevention; supports consensus on integrating local prevalence data into evidence-based guidelines.
OBJECTIVES: To develop an evidence-based clinical guideline for the prevention and management of cardiovascular diseases (CVDs) in Saudi Arabia, tailored to local epidemiology and healthcare needs. METHODS: A multidisciplinary task force comprising cardiologists, public health specialists, and epidemiologists from different healthcare sectors in Saudi Arabia developed the guideline. Evidence synthesis was based on a comprehensive literature review and adaptation of international guidelines, particularly the 2021 European Society of Cardiology recommendations, contextualized to the Saudi setting. RESULTS: The guideline provides recommendations for both primary and secondary CVD prevention. Primary prevention emphasizes risk assessment incorporating genetic, lifestyle, and clinical factors, as well as lipid and glucose profiling. Lifestyle modifications, including dietary changes, smoking cessation, physical activity, weight management, and psychosocial support, are prioritized. Pharmacologic therapy targets lipid levels, blood pressure, and glycemic control, tailored to individual risk categories. For secondary prevention, strategies include post-event risk stratification, comorbidity management (diabetes, hypertension, chronic kidney disease), and optimization of pharmacologic therapy for coronary artery disease, heart failure, cerebrovascular disease, and peripheral artery disease. Lifestyle interventions, supervised cardiac rehabilitation, and routine follow-up for complication monitoring and treatment adjustment are integral components. CONCLUSION: This guideline presents an updated, evidence-based framework specifically designed for the Saudi population, underscoring prevention, lifestyle modification, and optimized pharmacologic management to address the rising burden of CVDs.
No takes yet. Share an insight, caveat, or question.
AlRahimi et al. (2026) conducted a cross-sectional in Tobacco use (n=11,381). Tobacco use was evaluated on Current tobacco users. In 2019, the overall prevalence of current tobacco use among adults aged 15 years and older in Saudi Arabia was 19.8%, with higher usage among men (30.0%) than women (4.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: